BioCentury on BioBusiness,
With sanofi, GSK in hand, Regulus thinks it can handle 1-2 more big miRNA deals
A Handful Would Be Fine
Monday, June 28, 2010
Therapeutics Inc. has not yet put anything in the clinic from its
microRNA discovery platform, but it has translated the technology's potential
into a pair of lucrative deals with pharma partners before reaching its third
Two years after signing a discovery deal with a potential
value of more than $500 million with GlaxoSmithKline
plc, Regulus last week entered a partnership with sanofi-aventis
Group that could turn out to be even bigger. The biotech thinks it has the
bandwidth to do another deal or two over the next couple of years, but
recognizes the importance of ring-fencing a few programs to build its own
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]